PRMT5 and familial pancreatic carcinoma: In addition to isogenic MTAP cell lines, we addressed differential sensitivity between MTAP-proficient and deficient cells towards PRMT5 inhibition in a panel of pancreatic cancer and non-transformed but immortalized cell lines that differ in MTAP status.